董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin Koch | 男 | President, Chief Executive Officer and Director | 64 | 169.00万美元 | 未持股 | 2025-11-19 |
| Badreddin Edris | 男 | Director | 38 | 1.67万美元 | 未持股 | 2025-11-19 |
| Jonathan Root | 男 | Director | 66 | 未披露 | 未持股 | 2025-11-19 |
| Alan Russell | 男 | Chief Scientific Officer and Director | 56 | 116.50万美元 | 未持股 | 2025-11-19 |
| Jonathan Fox | 男 | Director | 67 | 未披露 | 未持股 | 2025-11-19 |
| Christopher Martin | 男 | Director | 49 | 未披露 | 未持股 | 2025-11-19 |
| Peter Thompson | 男 | Director and Chairperson | 65 | 未披露 | 未持股 | 2025-11-19 |
| Laura Brege | 女 | Director | 67 | 11.08万美元 | 未持股 | 2025-11-19 |
| Arlene M. Morris | 女 | Director | 73 | 未披露 | 未持股 | 2025-11-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joanne M. Donovan | 女 | Chief Medical Officer | 68 | 未披露 | 未持股 | 2025-11-19 |
| John Moore | 男 | General Counsel | 60 | 未披露 | 未持股 | 2025-11-19 |
| Kevin Koch | 男 | President, Chief Executive Officer and Director | 64 | 169.00万美元 | 未持股 | 2025-11-19 |
| Alan Russell | 男 | Chief Scientific Officer and Director | 56 | 116.50万美元 | 未持股 | 2025-11-19 |
| Behrad Derakhshan | 男 | Chief Business Officer | 46 | 未披露 | 未持股 | 2025-11-19 |
| Robert Blaustein | 男 | Chief Operating Officer | 64 | 未披露 | 未持股 | 2025-11-19 |
| Michael Nofi | 男 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2025-11-19 |
董事简历
中英对照 | 中文 | 英文- Kevin Koch
-
Kevin Koch自2017年2月起担任Miragen Therapeutics, Inc.的董事。在加入Miragen Therapeutics, Inc.的董事会之前，他自2016年7月起担任Private Miragen的董事会成员。Kevin Koch自2017年6月起担任Edgewise Therapeutics, Inc.的董事会成员，自2017年8月起担任总裁兼首席执行官。他曾担任OrbiMed Advisors, LLC的风险合伙人（2016年5月以来）。加入OrbiMed之前，他曾担任生物技术行业的顾问（2015年9月至2016年5月）。在担任顾问之前，他曾担任Biogen, Inc.的高级副总裁，负责药物发现、化学和分子治疗（2013年12月至2015年9月）。加入Biogen之前，他创立Array BioPharma Inc.（上市生物制药公司），并担任其总裁、首席科学官和董事会成员（1998年5月至2013年11月）。在成立Array BioPharma Inc.之前，1995年至1998年，他是Amgen Inc.的蛋白酶抑制剂和新技术集团的药物化学副董事和项目负责人。从1988年到1995年，他在Pfizer, Inc.的中央研究部担任各种研究职位，包括高级研究员和高级研究科学家。他持有New York State大学 at Stony Brook的化学和生物化学学士学位，以及Rochester大学的合成有机化学博士学位。
Kevin Koch,has also been a Venture Partner with OrbiMed Advisors LLC, a healthcare investment firm, since 2016. Prior to joining OrbiMed, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to acting as a consultant, Dr. Koch was Senior Vice President for Drug Discovery (Chemical and Molecular Therapeutics) from December 2013 to September 2015 at Biogen Inc., a biotechnology company developing treatments for neurological diseases. Prior to joining Biogen, Dr. Koch co-founded Array BioPharma Inc., a clinical-stage pharmaceutical company, in February 1998, was President and Chief Scientific Officer from June 1998 to November 2013, and served on its board of directors from May 1998 to April 2012. Previously, Dr. Koch was Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to May 1998 at Amgen Inc., a biotechnological company addressing diseases with limited treatment options. From September 1988 until May 1995, Dr. Koch held various positions with Pfizer Central Research, a global pharmaceutical company, including Senior Research Investigator and Project Coordinator for the cellular migration and immunology project teams. Dr. Koch currently serves on the board of directors of Neurogastrx, Inc. and previously served on the board of directors of Terremoto Biosciences from July 2021 to December 2023, both privately held biotechnology companies. Dr. Koch also previously served as a member of the board of directors of Miragen Therapeutics, Inc., a public biotechnology company advancing new treatments for underserved diseases. Dr. Koch received a B.S. in chemistry and in biochemistry from the State University of New York at Stony Brook and a Ph.D. in organic chemistry from the University of Rochester. - Kevin Koch自2017年2月起担任Miragen Therapeutics, Inc.的董事。在加入Miragen Therapeutics, Inc.的董事会之前，他自2016年7月起担任Private Miragen的董事会成员。Kevin Koch自2017年6月起担任Edgewise Therapeutics, Inc.的董事会成员，自2017年8月起担任总裁兼首席执行官。他曾担任OrbiMed Advisors, LLC的风险合伙人（2016年5月以来）。加入OrbiMed之前，他曾担任生物技术行业的顾问（2015年9月至2016年5月）。在担任顾问之前，他曾担任Biogen, Inc.的高级副总裁，负责药物发现、化学和分子治疗（2013年12月至2015年9月）。加入Biogen之前，他创立Array BioPharma Inc.（上市生物制药公司），并担任其总裁、首席科学官和董事会成员（1998年5月至2013年11月）。在成立Array BioPharma Inc.之前，1995年至1998年，他是Amgen Inc.的蛋白酶抑制剂和新技术集团的药物化学副董事和项目负责人。从1988年到1995年，他在Pfizer, Inc.的中央研究部担任各种研究职位，包括高级研究员和高级研究科学家。他持有New York State大学 at Stony Brook的化学和生物化学学士学位，以及Rochester大学的合成有机化学博士学位。
- Kevin Koch,has also been a Venture Partner with OrbiMed Advisors LLC, a healthcare investment firm, since 2016. Prior to joining OrbiMed, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to acting as a consultant, Dr. Koch was Senior Vice President for Drug Discovery (Chemical and Molecular Therapeutics) from December 2013 to September 2015 at Biogen Inc., a biotechnology company developing treatments for neurological diseases. Prior to joining Biogen, Dr. Koch co-founded Array BioPharma Inc., a clinical-stage pharmaceutical company, in February 1998, was President and Chief Scientific Officer from June 1998 to November 2013, and served on its board of directors from May 1998 to April 2012. Previously, Dr. Koch was Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to May 1998 at Amgen Inc., a biotechnological company addressing diseases with limited treatment options. From September 1988 until May 1995, Dr. Koch held various positions with Pfizer Central Research, a global pharmaceutical company, including Senior Research Investigator and Project Coordinator for the cellular migration and immunology project teams. Dr. Koch currently serves on the board of directors of Neurogastrx, Inc. and previously served on the board of directors of Terremoto Biosciences from July 2021 to December 2023, both privately held biotechnology companies. Dr. Koch also previously served as a member of the board of directors of Miragen Therapeutics, Inc., a public biotechnology company advancing new treatments for underserved diseases. Dr. Koch received a B.S. in chemistry and in biochemistry from the State University of New York at Stony Brook and a Ph.D. in organic chemistry from the University of Rochester.
- Badreddin Edris
-
Badreddin Edris自2021年2月以来一直担任我们的董事会成员。Edris博士共同创立了公司，自2018年3月起担任我们的战略顾问，并于2017年5月至2018年3月担任运营职务。Edris博士自2021年1月起担任临床阶段生物制药公司SpringWorksTherapeutics，Inc.的首席运营官，此前曾于2018年9月至2020年12月担任Springworks的首席商务官。此前，Edris博士曾于2014年6月至2018年11月担任梦百合投资公司OrbiMed Advisors LLC私募股权团队的投资和运营专业人士。在OrbiMed期间，Edris博士还在OrbiMed投资组合公司SilverbackTherapeutics，Inc.共同创立并担任运营职务，他于2016年4月至2018年3月担任公司发展主管，并于2018年4月至2018年9月担任首席商务官。在OrbiMed之前，Edris博士是贝恩公司（Bain&Co Inc.）梦百合业务的管理顾问。Edris博士在韦伯州立大学（Weber State University）获得微生物学学士学位，在斯坦福大学（Stanford University）获得生物学硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得遗传学博士学位，他是该校的国家科学基金会研究生研究员。
Badreddin Edris,co-founded the Company and served in an operational role from May 2017 until March 2018 before transitioning into an advisory role. Since January 2021, Dr. Edris has been the Chief Operating Officer of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and was previously the Chief Business Officer of SpringWorks from September 2018 to December 2020. Previously, Dr. Edris was an investment and operating professional on the private equity team at OrbiMed Advisors LLC, a healthcare investment firm, from June 2014 to November 2018. While at OrbiMed, Dr. Edris also co-founded and held an operating role at Silverback Therapeutics, Inc., an OrbiMed portfolio company, where he was Head of Corporate Development from April 2016 to March 2018 and Chief Business Officer from April 2018 to September 2018. Before OrbiMed, Dr. Edris was a management consultant in the healthcare practice at Bain & Co Inc. Dr. Edris received a B.I.S. in microbiology from Weber State University, a M.S. in biology from Stanford University and a Ph.D. in genetics from Stanford University School of Medicine, where he was a National Science Foundation Graduate Research Fellow. - Badreddin Edris自2021年2月以来一直担任我们的董事会成员。Edris博士共同创立了公司，自2018年3月起担任我们的战略顾问，并于2017年5月至2018年3月担任运营职务。Edris博士自2021年1月起担任临床阶段生物制药公司SpringWorksTherapeutics，Inc.的首席运营官，此前曾于2018年9月至2020年12月担任Springworks的首席商务官。此前，Edris博士曾于2014年6月至2018年11月担任梦百合投资公司OrbiMed Advisors LLC私募股权团队的投资和运营专业人士。在OrbiMed期间，Edris博士还在OrbiMed投资组合公司SilverbackTherapeutics，Inc.共同创立并担任运营职务，他于2016年4月至2018年3月担任公司发展主管，并于2018年4月至2018年9月担任首席商务官。在OrbiMed之前，Edris博士是贝恩公司（Bain&Co Inc.）梦百合业务的管理顾问。Edris博士在韦伯州立大学（Weber State University）获得微生物学学士学位，在斯坦福大学（Stanford University）获得生物学硕士学位，并在斯坦福大学医学院（Stanford University School of Medicine）获得遗传学博士学位，他是该校的国家科学基金会研究生研究员。
- Badreddin Edris,co-founded the Company and served in an operational role from May 2017 until March 2018 before transitioning into an advisory role. Since January 2021, Dr. Edris has been the Chief Operating Officer of SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and was previously the Chief Business Officer of SpringWorks from September 2018 to December 2020. Previously, Dr. Edris was an investment and operating professional on the private equity team at OrbiMed Advisors LLC, a healthcare investment firm, from June 2014 to November 2018. While at OrbiMed, Dr. Edris also co-founded and held an operating role at Silverback Therapeutics, Inc., an OrbiMed portfolio company, where he was Head of Corporate Development from April 2016 to March 2018 and Chief Business Officer from April 2018 to September 2018. Before OrbiMed, Dr. Edris was a management consultant in the healthcare practice at Bain & Co Inc. Dr. Edris received a B.I.S. in microbiology from Weber State University, a M.S. in biology from Stanford University and a Ph.D. in genetics from Stanford University School of Medicine, where he was a National Science Foundation Graduate Research Fellow.
- Jonathan Root
-
Jonathan Root自2019年8月起担任EdgewiseTherapeutics，Inc.董事会成员。Root自1998年1月起担任多个U.S.Venture Partners’Funds管理成员。Root博士自2020年3月起担任SilverbackTherapeutics，Inc.董事会成员，自2011年9月起担任InariMedical，Inc.董事会成员，后者是一家专注于治疗大块血栓的医疗技术公司。此前，Root博士曾于2004年8月至2019年4月担任OncomedPharmaceuticals，Inc.（一家开发癌症疗法的上市制药公司）的董事会成员。此外，Root博士目前在梦百合行业的几家私营公司的董事会任职。Root博士在达特茅斯学院（Dartmouth College）获得经济学学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在佛罗里达大学医学院（University of Florida College of Medicine）获得医学博士学位。
Jonathan Root,served as a board member of Inari Medical, Inc., a medical technology company focusing on treatment of venous thromboembolism acquired by Stryker Corporation in February 2025, from September 2011 to February 2025, OncoMed Pharmaceuticals, Inc., a biopharmaceutical company developing cancer therapeutics, from August 2004 to April 2019, eFFECTOR Therapeutics, Inc., a pharmaceutical company developing cancer therapeutics, from April 2014 to February 2022, and Silverback Therapeutics, Inc., a biopharmaceutical company developing cancer treatment therapies acquired by ARS Pharmaceuticals in November 2022, from March 2020 to November 2022. Additionally, Dr. Root currently serves on the board of directors of several private companies in the healthcare industry. Dr. Root received an A.B. in economics from Dartmouth College, an M.D. from the University of Florida College of Medicine and an M.B.A. from Columbia Business School. - Jonathan Root自2019年8月起担任EdgewiseTherapeutics，Inc.董事会成员。Root自1998年1月起担任多个U.S.Venture Partners’Funds管理成员。Root博士自2020年3月起担任SilverbackTherapeutics，Inc.董事会成员，自2011年9月起担任InariMedical，Inc.董事会成员，后者是一家专注于治疗大块血栓的医疗技术公司。此前，Root博士曾于2004年8月至2019年4月担任OncomedPharmaceuticals，Inc.（一家开发癌症疗法的上市制药公司）的董事会成员。此外，Root博士目前在梦百合行业的几家私营公司的董事会任职。Root博士在达特茅斯学院（Dartmouth College）获得经济学学士学位，在哥伦比亚商学院（Columbia Business School）获得工商管理硕士学位，在佛罗里达大学医学院（University of Florida College of Medicine）获得医学博士学位。
- Jonathan Root,served as a board member of Inari Medical, Inc., a medical technology company focusing on treatment of venous thromboembolism acquired by Stryker Corporation in February 2025, from September 2011 to February 2025, OncoMed Pharmaceuticals, Inc., a biopharmaceutical company developing cancer therapeutics, from August 2004 to April 2019, eFFECTOR Therapeutics, Inc., a pharmaceutical company developing cancer therapeutics, from April 2014 to February 2022, and Silverback Therapeutics, Inc., a biopharmaceutical company developing cancer treatment therapies acquired by ARS Pharmaceuticals in November 2022, from March 2020 to November 2022. Additionally, Dr. Root currently serves on the board of directors of several private companies in the healthcare industry. Dr. Root received an A.B. in economics from Dartmouth College, an M.D. from the University of Florida College of Medicine and an M.B.A. from Columbia Business School.
- Alan Russell
-
Alan Russell联合创立了公司，自2017年8月起担任董事会成员，自2017年6月起担任首席科学官。此前，Russell博士曾于2014年9月至2017年6月担任跨国制药公司GlaxoSmithKline plc Vice President兼肌肉代谢发现绩效单位负责人，并于2010年3月至2014年9月担任肌肉代谢发现绩效单位董事兼生物学负责人。加入GlaxoSmithKline之前，Russell从2002年2月到2010年2月担任Cytokinetics，Inc.（一家生物制药公司，开发肌肉功能受损疾病的治疗方法）肌肉生物学和治疗副董事。他自2017年11月起担任科罗拉多大学博尔德分校综合生理系兼职教授。Russell医生收到了B.Pharm.Bath大学的药学和药理学博士学位以及细胞生物学和基因治疗博士学位，是Stanford大学医学院的博士后。
Alan Russell,was Vice President and Head of the Muscle Metabolism Discovery Performance Unit from September 2014 to June 2017 and Director and Head of Biology of the Muscle Metabolism Discovery Performance Unit from March 2010 to September 2014 at GlaxoSmithKline plc, a multinational pharmaceutical company. Prior to joining GlaxoSmithKline, Dr. Russell was Associate Director of Muscle Biology and Therapeutics from February 2002 to February 2010 at Cytokinetics, Inc., a biopharmaceutical company developing treatments for diseases of impaired muscle function. He has been Adjunct Professor in the Department of Integrative Physiology at the University of Colorado Boulder since November 2017. Dr. Russell received a B.Pharm. in pharmacy and pharmacology and a Ph.D. in cell biology and gene therapy from the University of Bath and was Postdoctoral Fellow at the Stanford University School of Medicine. - Alan Russell联合创立了公司，自2017年8月起担任董事会成员，自2017年6月起担任首席科学官。此前，Russell博士曾于2014年9月至2017年6月担任跨国制药公司GlaxoSmithKline plc Vice President兼肌肉代谢发现绩效单位负责人，并于2010年3月至2014年9月担任肌肉代谢发现绩效单位董事兼生物学负责人。加入GlaxoSmithKline之前，Russell从2002年2月到2010年2月担任Cytokinetics，Inc.（一家生物制药公司，开发肌肉功能受损疾病的治疗方法）肌肉生物学和治疗副董事。他自2017年11月起担任科罗拉多大学博尔德分校综合生理系兼职教授。Russell医生收到了B.Pharm.Bath大学的药学和药理学博士学位以及细胞生物学和基因治疗博士学位，是Stanford大学医学院的博士后。
- Alan Russell,was Vice President and Head of the Muscle Metabolism Discovery Performance Unit from September 2014 to June 2017 and Director and Head of Biology of the Muscle Metabolism Discovery Performance Unit from March 2010 to September 2014 at GlaxoSmithKline plc, a multinational pharmaceutical company. Prior to joining GlaxoSmithKline, Dr. Russell was Associate Director of Muscle Biology and Therapeutics from February 2002 to February 2010 at Cytokinetics, Inc., a biopharmaceutical company developing treatments for diseases of impaired muscle function. He has been Adjunct Professor in the Department of Integrative Physiology at the University of Colorado Boulder since November 2017. Dr. Russell received a B.Pharm. in pharmacy and pharmacology and a Ph.D. in cell biology and gene therapy from the University of Bath and was Postdoctoral Fellow at the Stanford University School of Medicine.
- Jonathan Fox
-
Jonathan Fox，曾于2013年至2016年担任MyoKardia，Inc.的首席医疗官，该公司是一家临床阶段的生物制药公司，专注于严重心血管疾病的靶向治疗，并于2016年至2017年担任高级顾问。此外，他于2012年至2013年在技术研究和咨询公司Nigel-Montgomery，LLC担任顾问，曾于1998年至2012年先后在医药制造公司SmithKline BeeCham、默沙东研究实验室、默克制药公司公司的研发部门以及专注于肿瘤学、罕见病和各种生物制药应用的生物制药公司阿斯利康担任多个高级职位。1993年至2013年，他还在宾夕法尼亚大学医学院任教。自2013年起，他在斯坦福大学心血管研究所担任兼职教职。Fox博士是ML BioSolutions的董事会成员，ML BioSolutions是一家专注于开发四肢带肌营养不良症口服疗法的私营公司，也是非营利组织兰克瑙医学研究所的受托人。他在芝加哥大学获得了生物学A.B.、实验病理学博士和医学博士学位，并在杜克大学完成了内科和心脏病学培训。Fox博士在心血管疾病领域获得ABIM认证，是美国心脏病学会的研究员。
Jonathan Fox,served as the Chief Medical Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company focused on targeted therapies for serious cardiovascular diseases, from 2013 to 2016 and as a senior advisor from 2016 to 2017. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, a technology research and advisory company, from 2012 to 2013 and held various senior positions successively at SmithKline Beecham, a pharmaceutical manufacturing company, Merck Research Laboratories, the research and development division of Merck & Co., Inc., and AstraZeneca, a biopharmaceutical company focused on oncology, rare diseases, and various biopharmaceutical applications, from 1998 to 2012. He was also on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. Since 2013, he has held an adjunct faculty position at the Stanford University Cardiovascular Institute. Dr. Fox serves on the board at ML BioSolutions, a private company focused on developing an oral treatment for limb girdle muscular dystrophy, and is a trustee of the Lankenau Institute for Medical Research, a nonprofit organization. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology. - Jonathan Fox，曾于2013年至2016年担任MyoKardia，Inc.的首席医疗官，该公司是一家临床阶段的生物制药公司，专注于严重心血管疾病的靶向治疗，并于2016年至2017年担任高级顾问。此外，他于2012年至2013年在技术研究和咨询公司Nigel-Montgomery，LLC担任顾问，曾于1998年至2012年先后在医药制造公司SmithKline BeeCham、默沙东研究实验室、默克制药公司公司的研发部门以及专注于肿瘤学、罕见病和各种生物制药应用的生物制药公司阿斯利康担任多个高级职位。1993年至2013年，他还在宾夕法尼亚大学医学院任教。自2013年起，他在斯坦福大学心血管研究所担任兼职教职。Fox博士是ML BioSolutions的董事会成员，ML BioSolutions是一家专注于开发四肢带肌营养不良症口服疗法的私营公司，也是非营利组织兰克瑙医学研究所的受托人。他在芝加哥大学获得了生物学A.B.、实验病理学博士和医学博士学位，并在杜克大学完成了内科和心脏病学培训。Fox博士在心血管疾病领域获得ABIM认证，是美国心脏病学会的研究员。
- Jonathan Fox,served as the Chief Medical Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company focused on targeted therapies for serious cardiovascular diseases, from 2013 to 2016 and as a senior advisor from 2016 to 2017. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, a technology research and advisory company, from 2012 to 2013 and held various senior positions successively at SmithKline Beecham, a pharmaceutical manufacturing company, Merck Research Laboratories, the research and development division of Merck & Co., Inc., and AstraZeneca, a biopharmaceutical company focused on oncology, rare diseases, and various biopharmaceutical applications, from 1998 to 2012. He was also on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013. Since 2013, he has held an adjunct faculty position at the Stanford University Cardiovascular Institute. Dr. Fox serves on the board at ML BioSolutions, a private company focused on developing an oral treatment for limb girdle muscular dystrophy, and is a trustee of the Lankenau Institute for Medical Research, a nonprofit organization. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.
- Christopher Martin
-
Christopher Martin，于2024年1月至2025年10月在维罗纳制药担任首席商务官，该公司于2025年10月被默沙东公司以约100亿美元的价格收购。作为首席商务官，Martin先生负责构建公司首个产品发布Ohtuvayre的商业组织和发布策略（ensifentrine）。Martin先生此前曾担任维罗纳的其他管理职位，包括2022年1月至2023年12月的商务高级副总裁，以及2020年6月和2022年12月的商务副总裁。此前，他曾于2018年3月至2020年6月在SK Life Science担任市场营销执行总监，该公司专注于开发针对中枢神经系统疾病的新型疗法。Martin先生在制定商业和营销战略以及推出他们的第一个商业产品XCOPRI的框架方面发挥了重要作用（cenobamate片）。在被Melinta Therapeutics收购之前，Martin先生是Cempra的营销主管，在那里他领导了该公司第一个产品索利霉素的开发和发布战略。在加入Cempra之前，他曾在柳药医疗任职10年，担任与日俱增的职责，并领导了Xifaxan公司被Valeant Pharmaceuticals收购期间的营销团队。Martin先生获得了克莱姆森大学财务管理理学学士学位。
Christopher Martin,served as Chief Commercial Officer from January 2024 to October 2025 for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October 2025. As Chief Commercial Officer, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre (ensifentrine). Mr. Martin previously served in other management positions at Verona, including Senior Vice President of Commercial from January 2022 to December 2023 and Vice President of Commercial from June 2020 and December 2022. Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions from March 2018 to June 2020. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. - Christopher Martin，于2024年1月至2025年10月在维罗纳制药担任首席商务官，该公司于2025年10月被默沙东公司以约100亿美元的价格收购。作为首席商务官，Martin先生负责构建公司首个产品发布Ohtuvayre的商业组织和发布策略（ensifentrine）。Martin先生此前曾担任维罗纳的其他管理职位，包括2022年1月至2023年12月的商务高级副总裁，以及2020年6月和2022年12月的商务副总裁。此前，他曾于2018年3月至2020年6月在SK Life Science担任市场营销执行总监，该公司专注于开发针对中枢神经系统疾病的新型疗法。Martin先生在制定商业和营销战略以及推出他们的第一个商业产品XCOPRI的框架方面发挥了重要作用（cenobamate片）。在被Melinta Therapeutics收购之前，Martin先生是Cempra的营销主管，在那里他领导了该公司第一个产品索利霉素的开发和发布战略。在加入Cempra之前，他曾在柳药医疗任职10年，担任与日俱增的职责，并领导了Xifaxan公司被Valeant Pharmaceuticals收购期间的营销团队。Martin先生获得了克莱姆森大学财务管理理学学士学位。
- Christopher Martin,served as Chief Commercial Officer from January 2024 to October 2025 for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October 2025. As Chief Commercial Officer, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre (ensifentrine). Mr. Martin previously served in other management positions at Verona, including Senior Vice President of Commercial from January 2022 to December 2023 and Vice President of Commercial from June 2020 and December 2022. Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions from March 2018 to June 2020. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University.
- Peter Thompson
-
Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
- Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
- Laura Brege
-
Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc., each public companies, and T-knife Therapeutics, Inc., a privately held company. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation, HLS Therapeutics, Inc. and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. - Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
- Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc., each public companies, and T-knife Therapeutics, Inc., a privately held company. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation, HLS Therapeutics, Inc. and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
- Arlene M. Morris
-
Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
Arlene M. Morris,has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a publicly traded therapeutic antibody company, Cogent Biosciences, Inc. (Nasdaq: COGT), a publicly traded oncology biopharmaceutical company, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, and is a director (since February 2022) and currently chair of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company. She was previously a director of Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College. - Arlene M. Morris，她一直担任Palatin的董事（2015年6月以来）。自2015年5月起，她担任Willow Advisors, LLC（生物技术公司的业务发展、商业发展和企业战略咨询公司）的首席执行官。2012年4月至2015年5月，她担任Syndax Pharmaceuticals, Inc.（一家私营生物制药公司，专注于治疗耐药癌症的表观遗传疗法的开发和商业化）的总裁兼首席执行官，并于2011年5月至2015年5月担任董事会成员。2003年至2011年1月，她担任Affymax, Inc.（上市的生物技术公司）的总裁、首席执行官和董事会成员。她还曾在Clearview Projects, Inc.（企业咨询公司）、Coulter Pharmaceutical, Inc.（公开上市的制药公司）、Scios Inc.（公开上市的生物制药公司）和Johnson & Johnson（公开上市的医疗保健公司）担任各种管理和执行职位。她目前是Viridian Therapeutics, Inc.（公开交易的治疗抗体公司）和Cogent Biosciences, Inc.（公开交易的肿瘤生物制药公司）的董事会成员，并曾担任Viveve Medical, Inc.（公开交易的女性医疗保健医疗设备公司）的董事，直到2023年2月，Neovacs SA（公开交易的法国公司），Biodel Inc.（公开交易的专业制药公司）。从2015年到2016年与Albireo Limited和Dimension Therapeutics, Inc.（上市的基因治疗公司）合并，直到2017年被Ultragenyx Pharmaceutical Inc.收购。她持有Carlow College的生物和化学学士学位。
- Arlene M. Morris,has been a director of Palatin since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC, a consultancy to biotech companies on business development, commercial development and corporate strategy. From April 2012 until May 2015, she was President and Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers and was a member of the board of directors from May 2011 until May 2015. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viridian Therapeutics, Inc. (Nasdaq: VRDN), a publicly traded therapeutic antibody company, Cogent Biosciences, Inc. (Nasdaq: COGT), a publicly traded oncology biopharmaceutical company, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, and is a director (since February 2022) and currently chair of TC Biopharm (Holdings) PLC (Nasdaq: TCBP), a United Kingdom biopharmaceutical company. She was previously a director of Viveve Medical, Inc., a publicly traded female healthcare medical device company, until February 2023, Neovacs SA, a publicly traded French company, Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016, and Dimension Therapeutics, Inc., a publicly traded gene therapy company, until its acquisition by Ultragenyx Pharmaceutical Inc. in 2017. Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.
高管简历
中英对照 | 中文 | 英文- Joanne M. Donovan
Joanne M. Donovan，2011年7月以来，她一直担任首席医疗官。1989年以来，她曾担任the VA Boston Healthcare System的主治医师，在那里她曾担任胃肠病学主任。她曾任职Harvard Medical School（1990年以来），最近担任医学副临床教授。从1998年到2011年7月，她曾担任多种职务，并不断被提拔，最终担任Genzyme Corporation（公开上市的生物技术公司，她提供公司收购GelTex公司加入公司）的负责临床开发的副总裁。她持有the Massachusetts Institute of Technology的医学工程和医学物理学的博士学位、Harvard Medical School的医学博士学位，以及the Massachusetts Institute of Technology的理学士学位。她曾在the Brigham and Women's Hospital完成内科住院医师培训，胃肠病学研究。
Joanne M. Donovan, M.D., Ph.D., has served as Chief Medical Officer since July 2011. Since 1989 she has worked as a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990 most recently as associate clinical professor of medicine. From 1998 to July 2011 Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women's Hospital.- Joanne M. Donovan，2011年7月以来，她一直担任首席医疗官。1989年以来，她曾担任the VA Boston Healthcare System的主治医师，在那里她曾担任胃肠病学主任。她曾任职Harvard Medical School（1990年以来），最近担任医学副临床教授。从1998年到2011年7月，她曾担任多种职务，并不断被提拔，最终担任Genzyme Corporation（公开上市的生物技术公司，她提供公司收购GelTex公司加入公司）的负责临床开发的副总裁。她持有the Massachusetts Institute of Technology的医学工程和医学物理学的博士学位、Harvard Medical School的医学博士学位，以及the Massachusetts Institute of Technology的理学士学位。她曾在the Brigham and Women's Hospital完成内科住院医师培训，胃肠病学研究。
- Joanne M. Donovan, M.D., Ph.D., has served as Chief Medical Officer since July 2011. Since 1989 she has worked as a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990 most recently as associate clinical professor of medicine. From 1998 to July 2011 Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women's Hospital.
- John Moore
John Moore，他于2012年2月被任命为董事。他曾一直担任Array BioPharma公司的副总裁、总法律顾问兼秘书（2002年以来）。他持有North Carolina大学Chapel Hill分校法学院的法学博士学位、Illinois大学Urbana-Champaign生物化学硕士学位，以及North Carolina大学Chapel Hill的化学学士学位。
John Moore,was General Counsel and Corporate Secretary from November 2018 to September 2019 at Peloton Therapeutics, Inc., a cancer drug development company acquired by Merck & Co., Inc., a pharmaceutical company. Mr. Moore also provided consulting and legal services to various small companies and non-profit groups from November 2018 to September 2019. Mr. Moore was Vice President and General Counsel from March 2002 to September 2017 and Corporate Secretary from October 2002 to September 2017 at Array BioPharma Inc. Prior to Array, Mr. Moore was an attorney at Wilson Sonsini Goodrich & Rosati, P.C., Kenyon & Kenyon LLP and Arnold White & Durkee P.C. He previously served on the board of directors of Nivalis Therapeutics, Inc. from February 2012 to July 2017. Mr. Moore received a B.S. in chemistry from the University of North Carolina at Chapel Hill, an M.S. in biochemistry from the University of Illinois at Urbana-Champaign and a J.D. from the University of North Carolina at Chapel Hill School of Law.- John Moore，他于2012年2月被任命为董事。他曾一直担任Array BioPharma公司的副总裁、总法律顾问兼秘书（2002年以来）。他持有North Carolina大学Chapel Hill分校法学院的法学博士学位、Illinois大学Urbana-Champaign生物化学硕士学位，以及North Carolina大学Chapel Hill的化学学士学位。
- John Moore,was General Counsel and Corporate Secretary from November 2018 to September 2019 at Peloton Therapeutics, Inc., a cancer drug development company acquired by Merck & Co., Inc., a pharmaceutical company. Mr. Moore also provided consulting and legal services to various small companies and non-profit groups from November 2018 to September 2019. Mr. Moore was Vice President and General Counsel from March 2002 to September 2017 and Corporate Secretary from October 2002 to September 2017 at Array BioPharma Inc. Prior to Array, Mr. Moore was an attorney at Wilson Sonsini Goodrich & Rosati, P.C., Kenyon & Kenyon LLP and Arnold White & Durkee P.C. He previously served on the board of directors of Nivalis Therapeutics, Inc. from February 2012 to July 2017. Mr. Moore received a B.S. in chemistry from the University of North Carolina at Chapel Hill, an M.S. in biochemistry from the University of Illinois at Urbana-Champaign and a J.D. from the University of North Carolina at Chapel Hill School of Law.
- Kevin Koch
Kevin Koch自2017年2月起担任Miragen Therapeutics, Inc.的董事。在加入Miragen Therapeutics, Inc.的董事会之前，他自2016年7月起担任Private Miragen的董事会成员。Kevin Koch自2017年6月起担任Edgewise Therapeutics, Inc.的董事会成员，自2017年8月起担任总裁兼首席执行官。他曾担任OrbiMed Advisors, LLC的风险合伙人（2016年5月以来）。加入OrbiMed之前，他曾担任生物技术行业的顾问（2015年9月至2016年5月）。在担任顾问之前，他曾担任Biogen, Inc.的高级副总裁，负责药物发现、化学和分子治疗（2013年12月至2015年9月）。加入Biogen之前，他创立Array BioPharma Inc.（上市生物制药公司），并担任其总裁、首席科学官和董事会成员（1998年5月至2013年11月）。在成立Array BioPharma Inc.之前，1995年至1998年，他是Amgen Inc.的蛋白酶抑制剂和新技术集团的药物化学副董事和项目负责人。从1988年到1995年，他在Pfizer, Inc.的中央研究部担任各种研究职位，包括高级研究员和高级研究科学家。他持有New York State大学 at Stony Brook的化学和生物化学学士学位，以及Rochester大学的合成有机化学博士学位。
Kevin Koch,has also been a Venture Partner with OrbiMed Advisors LLC, a healthcare investment firm, since 2016. Prior to joining OrbiMed, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to acting as a consultant, Dr. Koch was Senior Vice President for Drug Discovery (Chemical and Molecular Therapeutics) from December 2013 to September 2015 at Biogen Inc., a biotechnology company developing treatments for neurological diseases. Prior to joining Biogen, Dr. Koch co-founded Array BioPharma Inc., a clinical-stage pharmaceutical company, in February 1998, was President and Chief Scientific Officer from June 1998 to November 2013, and served on its board of directors from May 1998 to April 2012. Previously, Dr. Koch was Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to May 1998 at Amgen Inc., a biotechnological company addressing diseases with limited treatment options. From September 1988 until May 1995, Dr. Koch held various positions with Pfizer Central Research, a global pharmaceutical company, including Senior Research Investigator and Project Coordinator for the cellular migration and immunology project teams. Dr. Koch currently serves on the board of directors of Neurogastrx, Inc. and previously served on the board of directors of Terremoto Biosciences from July 2021 to December 2023, both privately held biotechnology companies. Dr. Koch also previously served as a member of the board of directors of Miragen Therapeutics, Inc., a public biotechnology company advancing new treatments for underserved diseases. Dr. Koch received a B.S. in chemistry and in biochemistry from the State University of New York at Stony Brook and a Ph.D. in organic chemistry from the University of Rochester.- Kevin Koch自2017年2月起担任Miragen Therapeutics, Inc.的董事。在加入Miragen Therapeutics, Inc.的董事会之前，他自2016年7月起担任Private Miragen的董事会成员。Kevin Koch自2017年6月起担任Edgewise Therapeutics, Inc.的董事会成员，自2017年8月起担任总裁兼首席执行官。他曾担任OrbiMed Advisors, LLC的风险合伙人（2016年5月以来）。加入OrbiMed之前，他曾担任生物技术行业的顾问（2015年9月至2016年5月）。在担任顾问之前，他曾担任Biogen, Inc.的高级副总裁，负责药物发现、化学和分子治疗（2013年12月至2015年9月）。加入Biogen之前，他创立Array BioPharma Inc.（上市生物制药公司），并担任其总裁、首席科学官和董事会成员（1998年5月至2013年11月）。在成立Array BioPharma Inc.之前，1995年至1998年，他是Amgen Inc.的蛋白酶抑制剂和新技术集团的药物化学副董事和项目负责人。从1988年到1995年，他在Pfizer, Inc.的中央研究部担任各种研究职位，包括高级研究员和高级研究科学家。他持有New York State大学 at Stony Brook的化学和生物化学学士学位，以及Rochester大学的合成有机化学博士学位。
- Kevin Koch,has also been a Venture Partner with OrbiMed Advisors LLC, a healthcare investment firm, since 2016. Prior to joining OrbiMed, Dr. Koch acted as a consultant in the biotech industry from September 2015 to May 2016. Prior to acting as a consultant, Dr. Koch was Senior Vice President for Drug Discovery (Chemical and Molecular Therapeutics) from December 2013 to September 2015 at Biogen Inc., a biotechnology company developing treatments for neurological diseases. Prior to joining Biogen, Dr. Koch co-founded Array BioPharma Inc., a clinical-stage pharmaceutical company, in February 1998, was President and Chief Scientific Officer from June 1998 to November 2013, and served on its board of directors from May 1998 to April 2012. Previously, Dr. Koch was Associate Director of Medicinal Chemistry and Project Leader for the Protease Inhibitor and New Leads project teams from May 1995 to May 1998 at Amgen Inc., a biotechnological company addressing diseases with limited treatment options. From September 1988 until May 1995, Dr. Koch held various positions with Pfizer Central Research, a global pharmaceutical company, including Senior Research Investigator and Project Coordinator for the cellular migration and immunology project teams. Dr. Koch currently serves on the board of directors of Neurogastrx, Inc. and previously served on the board of directors of Terremoto Biosciences from July 2021 to December 2023, both privately held biotechnology companies. Dr. Koch also previously served as a member of the board of directors of Miragen Therapeutics, Inc., a public biotechnology company advancing new treatments for underserved diseases. Dr. Koch received a B.S. in chemistry and in biochemistry from the State University of New York at Stony Brook and a Ph.D. in organic chemistry from the University of Rochester.
- Alan Russell
Alan Russell联合创立了公司，自2017年8月起担任董事会成员，自2017年6月起担任首席科学官。此前，Russell博士曾于2014年9月至2017年6月担任跨国制药公司GlaxoSmithKline plc Vice President兼肌肉代谢发现绩效单位负责人，并于2010年3月至2014年9月担任肌肉代谢发现绩效单位董事兼生物学负责人。加入GlaxoSmithKline之前，Russell从2002年2月到2010年2月担任Cytokinetics，Inc.（一家生物制药公司，开发肌肉功能受损疾病的治疗方法）肌肉生物学和治疗副董事。他自2017年11月起担任科罗拉多大学博尔德分校综合生理系兼职教授。Russell医生收到了B.Pharm.Bath大学的药学和药理学博士学位以及细胞生物学和基因治疗博士学位，是Stanford大学医学院的博士后。
Alan Russell,was Vice President and Head of the Muscle Metabolism Discovery Performance Unit from September 2014 to June 2017 and Director and Head of Biology of the Muscle Metabolism Discovery Performance Unit from March 2010 to September 2014 at GlaxoSmithKline plc, a multinational pharmaceutical company. Prior to joining GlaxoSmithKline, Dr. Russell was Associate Director of Muscle Biology and Therapeutics from February 2002 to February 2010 at Cytokinetics, Inc., a biopharmaceutical company developing treatments for diseases of impaired muscle function. He has been Adjunct Professor in the Department of Integrative Physiology at the University of Colorado Boulder since November 2017. Dr. Russell received a B.Pharm. in pharmacy and pharmacology and a Ph.D. in cell biology and gene therapy from the University of Bath and was Postdoctoral Fellow at the Stanford University School of Medicine.- Alan Russell联合创立了公司，自2017年8月起担任董事会成员，自2017年6月起担任首席科学官。此前，Russell博士曾于2014年9月至2017年6月担任跨国制药公司GlaxoSmithKline plc Vice President兼肌肉代谢发现绩效单位负责人，并于2010年3月至2014年9月担任肌肉代谢发现绩效单位董事兼生物学负责人。加入GlaxoSmithKline之前，Russell从2002年2月到2010年2月担任Cytokinetics，Inc.（一家生物制药公司，开发肌肉功能受损疾病的治疗方法）肌肉生物学和治疗副董事。他自2017年11月起担任科罗拉多大学博尔德分校综合生理系兼职教授。Russell医生收到了B.Pharm.Bath大学的药学和药理学博士学位以及细胞生物学和基因治疗博士学位，是Stanford大学医学院的博士后。
- Alan Russell,was Vice President and Head of the Muscle Metabolism Discovery Performance Unit from September 2014 to June 2017 and Director and Head of Biology of the Muscle Metabolism Discovery Performance Unit from March 2010 to September 2014 at GlaxoSmithKline plc, a multinational pharmaceutical company. Prior to joining GlaxoSmithKline, Dr. Russell was Associate Director of Muscle Biology and Therapeutics from February 2002 to February 2010 at Cytokinetics, Inc., a biopharmaceutical company developing treatments for diseases of impaired muscle function. He has been Adjunct Professor in the Department of Integrative Physiology at the University of Colorado Boulder since November 2017. Dr. Russell received a B.Pharm. in pharmacy and pharmacology and a Ph.D. in cell biology and gene therapy from the University of Bath and was Postdoctoral Fellow at the Stanford University School of Medicine.
- Behrad Derakhshan
Behrad Derakhshan自2020年9月起担任我们的首席商务官。此前，Derakhshan博士于2019年7月至2020年9月担任VectivBio（一家临床阶段，专注于罕见疾病的生物技术公司）的首席商务官。在加入VectivBio之前，Derakhshan博士于2017年4月至2019年6月担任Therachon业务开发主管Vice President，Therachon是一家临床阶段生物技术公司，于2019年被辉瑞公司收购。任职Therachon公司之前，他曾担任Alexion Pharmaceuticals公司的董事（2016年1月至2017年4月），负责业务发展和战略评估（2015年1月至2015年12月最初领导新产品全球商业见解和分析团队）。在加入Alexion之前，Derakhshan博士是国际管理咨询公司NavigantConsulting，Inc.and Easton Associates，LLC的管理顾问。Derakhshan博士在耶鲁医学院（Yale School of Medicine）进行博士后培训，并在纽约威尔·康奈尔医学（Weill Cornell Medicine）和英国萨里大学（University of Surrey）的联合项目中获得生物化学博士学位。他获得了一级荣誉BSC。在萨里大学生物化学专业获得优异成绩。
Behrad Derakhshan,was Vice President, Head of Business Development from April 2017 to June 2019 at Therachon, a clinical stage biotechnology company acquired by Pfizer Inc. in 2019. Prior to Therachon, he was a Director from January 2016 to April 2017 at Alexion Pharmaceuticals responsible for Business Development and Strategic Evaluation after initially leading the New Products Global Commercial Insights and Analytics team from January 2015 to December 2015. Prior to joining Alexion, Dr. Derakhshan was a management consultant at Navigant Consulting, Inc. and Easton Associates, LLC, international management consulting firms. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in Biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK. He received a First-Class Honors BSc. with distinction in Biochemistry from the University of Surrey.- Behrad Derakhshan自2020年9月起担任我们的首席商务官。此前，Derakhshan博士于2019年7月至2020年9月担任VectivBio（一家临床阶段，专注于罕见疾病的生物技术公司）的首席商务官。在加入VectivBio之前，Derakhshan博士于2017年4月至2019年6月担任Therachon业务开发主管Vice President，Therachon是一家临床阶段生物技术公司，于2019年被辉瑞公司收购。任职Therachon公司之前，他曾担任Alexion Pharmaceuticals公司的董事（2016年1月至2017年4月），负责业务发展和战略评估（2015年1月至2015年12月最初领导新产品全球商业见解和分析团队）。在加入Alexion之前，Derakhshan博士是国际管理咨询公司NavigantConsulting，Inc.and Easton Associates，LLC的管理顾问。Derakhshan博士在耶鲁医学院（Yale School of Medicine）进行博士后培训，并在纽约威尔·康奈尔医学（Weill Cornell Medicine）和英国萨里大学（University of Surrey）的联合项目中获得生物化学博士学位。他获得了一级荣誉BSC。在萨里大学生物化学专业获得优异成绩。
- Behrad Derakhshan,was Vice President, Head of Business Development from April 2017 to June 2019 at Therachon, a clinical stage biotechnology company acquired by Pfizer Inc. in 2019. Prior to Therachon, he was a Director from January 2016 to April 2017 at Alexion Pharmaceuticals responsible for Business Development and Strategic Evaluation after initially leading the New Products Global Commercial Insights and Analytics team from January 2015 to December 2015. Prior to joining Alexion, Dr. Derakhshan was a management consultant at Navigant Consulting, Inc. and Easton Associates, LLC, international management consulting firms. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in Biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK. He received a First-Class Honors BSc. with distinction in Biochemistry from the University of Surrey.
- Robert Blaustein
Robert Blaustein，曾在制药公司默克制药公司担任多个职务，包括于2023年6月至2025年1月在动脉粥样硬化和代谢临床研究部担任副总裁兼动脉粥样硬化科科长，并于2021年1月至2023年6月担任副总裁兼心力衰竭科科长。Blaustein先生领导了动脉粥样硬化领域的所有后期开发工作。此外，Blaustein先生于2017年10月至2023年6月担任默克-拜耳可溶性鸟苷酸环化酶合作公司联合开发委员会主席默沙东，于2018年12月至2022年9月担任Vericiguat产品开发团队的默沙东主席，并于2014年9月至2021年1月担任默沙东心血管疾病临床研究执行总监。在默沙东工作的15年多时间里，Blaustein博士为一系列心血管靶点的临床项目做出了贡献，并领导了动脉粥样硬化和心衰领域的临床开发。他的研究生培训包括布莱根妇女医院的医学住院医师、麻省总医院的心脏病学研究金培训，以及布兰迪斯大学生物化学系HHMMI研究员克里斯·米勒实验室的博士后研究金。随后，他加入了塔夫茨医学中心的教师队伍，负责运营一个由R01资助的实验室，研究离子通道蛋白。在塔夫茨大学，他担任心脏病学部的主治心脏病学家，是神经科学和生物化学部门的教员，并且是医学院医学博士医学科学家培训计划的联合主任。布劳斯坦博士在卫斯理大学获得数学学士学位，在阿尔伯特·爱因斯坦医学院获得医学博士学位，在阿尔伯特·爱因斯坦医学院获得神经科学博士学位。
Robert Blaustein,held various positions with Merck & Co., Inc., a pharmaceutical company, including as Associate Vice President and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department from June 2023 to January 2025, and as Associate Vice President and the Heart Failure Section Head from January 2021 to June 2023. Mr. Blaustein led all late phase development efforts in the Atherosclerosis space. Additionally, Mr. Blaustein served as Merck Chair of the Joint Development Committee, Merck-Bayer Soluble Guanylate Cyclase Collaboration from October 2017 to June 2023, as the Merck Chair of the Vericiguat Product Development Team from December 2018 to September 2022, and as Merck's Executive Director of Clinical Research, Cardiovascular Diseases from September 2014 to January 2021. During his 15+ years at Merck Dr. Blaustein contributed to clinical programs across a range of cardiovascular targets and led clinical development in the atherosclerosis and heart failure spaces. His post-graduate training included a medical residency at Brigham and Women's Hospital, cardiology fellowship training at Massachusetts General Hospital, and a post-doctoral fellowship in the lab of Chris Miller, an HHMI investigator in the Biochemistry Department at Brandeis University. He then joined the faculty of Tufts Medical Center running an R01-funded laboratory studying ion channel proteins. At Tufts he served as an attending cardiologist in the Cardiology Division, was a faculty member in the Neuroscience and Biochemistry Departments and was co-director of the medical school's MD-PhD Medical Scientist Training Program. Dr. Blaustein received a B.A. in mathematics from Wesleyan University, an M.D. from Albert Einstein College of Medicine, and a Ph.D. in neuroscience from Albert Einstein College of Medicine.- Robert Blaustein，曾在制药公司默克制药公司担任多个职务，包括于2023年6月至2025年1月在动脉粥样硬化和代谢临床研究部担任副总裁兼动脉粥样硬化科科长，并于2021年1月至2023年6月担任副总裁兼心力衰竭科科长。Blaustein先生领导了动脉粥样硬化领域的所有后期开发工作。此外，Blaustein先生于2017年10月至2023年6月担任默克-拜耳可溶性鸟苷酸环化酶合作公司联合开发委员会主席默沙东，于2018年12月至2022年9月担任Vericiguat产品开发团队的默沙东主席，并于2014年9月至2021年1月担任默沙东心血管疾病临床研究执行总监。在默沙东工作的15年多时间里，Blaustein博士为一系列心血管靶点的临床项目做出了贡献，并领导了动脉粥样硬化和心衰领域的临床开发。他的研究生培训包括布莱根妇女医院的医学住院医师、麻省总医院的心脏病学研究金培训，以及布兰迪斯大学生物化学系HHMMI研究员克里斯·米勒实验室的博士后研究金。随后，他加入了塔夫茨医学中心的教师队伍，负责运营一个由R01资助的实验室，研究离子通道蛋白。在塔夫茨大学，他担任心脏病学部的主治心脏病学家，是神经科学和生物化学部门的教员，并且是医学院医学博士医学科学家培训计划的联合主任。布劳斯坦博士在卫斯理大学获得数学学士学位，在阿尔伯特·爱因斯坦医学院获得医学博士学位，在阿尔伯特·爱因斯坦医学院获得神经科学博士学位。
- Robert Blaustein,held various positions with Merck & Co., Inc., a pharmaceutical company, including as Associate Vice President and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department from June 2023 to January 2025, and as Associate Vice President and the Heart Failure Section Head from January 2021 to June 2023. Mr. Blaustein led all late phase development efforts in the Atherosclerosis space. Additionally, Mr. Blaustein served as Merck Chair of the Joint Development Committee, Merck-Bayer Soluble Guanylate Cyclase Collaboration from October 2017 to June 2023, as the Merck Chair of the Vericiguat Product Development Team from December 2018 to September 2022, and as Merck's Executive Director of Clinical Research, Cardiovascular Diseases from September 2014 to January 2021. During his 15+ years at Merck Dr. Blaustein contributed to clinical programs across a range of cardiovascular targets and led clinical development in the atherosclerosis and heart failure spaces. His post-graduate training included a medical residency at Brigham and Women's Hospital, cardiology fellowship training at Massachusetts General Hospital, and a post-doctoral fellowship in the lab of Chris Miller, an HHMI investigator in the Biochemistry Department at Brandeis University. He then joined the faculty of Tufts Medical Center running an R01-funded laboratory studying ion channel proteins. At Tufts he served as an attending cardiologist in the Cardiology Division, was a faculty member in the Neuroscience and Biochemistry Departments and was co-director of the medical school's MD-PhD Medical Scientist Training Program. Dr. Blaustein received a B.A. in mathematics from Wesleyan University, an M.D. from Albert Einstein College of Medicine, and a Ph.D. in neuroscience from Albert Einstein College of Medicine.
- Michael Nofi
Michael Nofi，自2019年11月至2025年7月，在SpringWorks治疗公司担任了六年的首席会计官，负责指导财务运营，确保合规、准确的报告，并进行战略性财务规划，以支持从一家研发机构到一家全球性商业公司的业务增长。在加入SpringWorks之前，Nofi先生是Nature's Bounty Co.的首席会计官以及全球会计和企业FP & A副总裁。Nofi先生还曾在阿索尔达治疗、Allergan plc和Forest Laboratories担任高级财务职务。诺菲先生拥有维拉诺瓦大学会计学学士学位和工商管理硕士学位，是一名注册会计师。
Michael Nofi,served as Chief Accounting Officer of SpringWorks Therapeutics for six years from November 2019 to July 2025 where he directed financial operations, ensuring compliance, accurate reporting, and strategic financial planning to support the business growth from an R&D organization to a global commercial company. Prior to SpringWorks, Mr. Nofi was Chief Accounting Officer and Vice President of Global Accounting and Corporate FP&A at The Nature's Bounty Co. Mr. Nofi also held senior finance roles at Acorda Therapeutics, Allergan plc, and Forest Laboratories. Mr. Nofi holds a B.S. in accounting and an M.B.A. from Villanova University and is a Certified Public Accountant.- Michael Nofi，自2019年11月至2025年7月，在SpringWorks治疗公司担任了六年的首席会计官，负责指导财务运营，确保合规、准确的报告，并进行战略性财务规划，以支持从一家研发机构到一家全球性商业公司的业务增长。在加入SpringWorks之前，Nofi先生是Nature's Bounty Co.的首席会计官以及全球会计和企业FP & A副总裁。Nofi先生还曾在阿索尔达治疗、Allergan plc和Forest Laboratories担任高级财务职务。诺菲先生拥有维拉诺瓦大学会计学学士学位和工商管理硕士学位，是一名注册会计师。
- Michael Nofi,served as Chief Accounting Officer of SpringWorks Therapeutics for six years from November 2019 to July 2025 where he directed financial operations, ensuring compliance, accurate reporting, and strategic financial planning to support the business growth from an R&D organization to a global commercial company. Prior to SpringWorks, Mr. Nofi was Chief Accounting Officer and Vice President of Global Accounting and Corporate FP&A at The Nature's Bounty Co. Mr. Nofi also held senior finance roles at Acorda Therapeutics, Allergan plc, and Forest Laboratories. Mr. Nofi holds a B.S. in accounting and an M.B.A. from Villanova University and is a Certified Public Accountant.